The NxStage Medical Inc. (NXTM) Insider Sells $299,514.60 in Stock

The NxStage Medical Inc. (NXTM) Insider Sells $299,514.60 in Stock

NxStage Medical Inc. (NASDAQ:NXTM) insider Robert S. Brown sold 10,805 shares of NxStage Medical stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $27.72, for a total transaction of $299,514.60. Following the completion of the transaction, the insider now directly owns 55,362 shares in the company, valued at $1,534,634.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of NxStage Medical Inc. (NASDAQ:NXTM) opened at 26.30 on Friday. NxStage Medical Inc. has a 12 month low of $13.49 and a 12 month high of $28.36. The stock’s market capitalization is $1.70 billion. The firm’s 50 day moving average is $26.01 and its 200 day moving average is $24.32.

A number of large investors have recently made changes to their positions in NXTM. Price T Rowe Associates Inc. MD acquired a new stake in shares of NxStage Medical during the third quarter worth approximately $207,000. Chartwell Investment Partners LLC raised its stake in shares of NxStage Medical by 28.7% in the third quarter. Chartwell Investment Partners LLC now owns 406,005 shares of the medical device company’s stock worth $10,146,000 after buying an additional 90,485 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of NxStage Medical by 42.1% in the third quarter. Mackenzie Financial Corp now owns 55,370 shares of the medical device company’s stock worth $1,384,000 after buying an additional 16,401 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of NxStage Medical by 573.3% in the third quarter. Panagora Asset Management Inc. now owns 76,560 shares of the medical device company’s stock worth $1,913,000 after buying an additional 65,189 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. raised its stake in shares of NxStage Medical by 29.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 316,312 shares of the medical device company’s stock worth $7,905,000 after buying an additional 71,964 shares during the last quarter. Hedge funds and other institutional investors own 98.74% of the company’s stock.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of NxStage Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 5th. Canaccord Genuity set a $31.00 price objective on shares of NxStage Medical and gave the company a “buy” rating in a research note on Tuesday, December 20th. Finally, Northland Securities set a $35.00 price objective on shares of NxStage Medical and gave the company a “buy” rating in a research note on Friday, December 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $27.83.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

Related posts

Leave a Comment